ADMA Biologics
Ramsey
About ADMA Biologics
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $1.1B
- Funding stage: IPO
- Last round: Post-IPO Debt (Aug 2025)
- Ticker: nasdaq:ADMA
- Website: admabiologics.com
- Phone: (201)478-5552
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/adma-biologics-5157 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.